A liposome-based mycobacterial vaccine induces potent adult and neonatal multifunctional T cells through the exquisite targeting of dendritic cells

PLoS ONE

Volumn 4, Issue 6, 2009, Pages

  Kamath, Arun T ^a   Rochat, Anne Françoise ^a   Christensen, Dennis ^b   Agger, Else Marie ^b   Andersen, Peter ^b   Lambert, Paul Henri ^a   Siegrist, Claire Anne ^b  

^a UNIVERSITY OF GENEVA MEDICAL SCHOOL   (Switzerland)

^b STATENS SERUM INSTITUT   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

AG85B ESAT 6 FUSION PROTEIN; ALUMINUM POTASSIUM SULFATE; BCG VACCINE; CAF 01; CD40 ANTIGEN; CD86 ANTIGEN; GAMMA INTERFERON; GLYCOPROTEIN P 15095; INTERLEUKIN 17; INTERLEUKIN 5; LIPOSOME; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; CATION; IMMUNOLOGICAL ADJUVANT;

ADJUVANT CHEMOTHERAPY; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN EXPRESSION; ARTICLE; BACTERIAL GROWTH; BCG VACCINATION; BOVINE TUBERCULOSIS; CD4+ T LYMPHOCYTE; CELL ACTIVATION; COLONY FORMING UNIT; CONTROLLED STUDY; CROSS PRESENTATION; CYTOKINE PRODUCTION; DENDRITIC CELL; DRUG EFFICACY; DRUG FORMULATION; DRUG TARGETING; IMMUNE RESPONSE; IMMUNOGENICITY; IN VIVO STUDY; LIPOSOMAL DELIVERY; MOUSE; MYCOBACTERIUM BOVIS; NEWBORN; NONHUMAN; TARGET CELL; TH1 CELL; TH17 CELL; ANIMAL; BIOSYNTHESIS; C57BL MOUSE; CHEMISTRY; IMMUNOLOGY; LYMPH NODE; METABOLISM; PATHOLOGY; T LYMPHOCYTE;

BACTERIA (MICROORGANISMS); MURINAE;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; ANTIGENS, CD40; ANTIGENS, CD86; CATIONS; CD4-POSITIVE T-LYMPHOCYTES; DENDRITIC CELLS; LIPOSOMES; LYMPH NODES; MICE; MICE, INBRED C57BL; MYCOBACTERIUM BOVIS; T-LYMPHOCYTES; TUBERCULOSIS VACCINES;

EID: 66749092107     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0005771     Document Type: Article

References (52)

1. Hoft DF (2008) Tuberculosis vaccine development: goals, immunological design, and evaluation. Lancet 372: 164-175.
2. Baumann S, Nasser Eddine A, Kaufmann SH (2006) Progress in tuberculosis vaccine development. Curr Opin Immunol 18: 438-448.
3. Kaufmann SH (2008) Rational design of novel antibacterial vaccines with an emphasis on tuberculosis. Scand J Infect Dis 40: 595-600.
4. Giri PK (2008) How could we have better vaccines against tuberculosis? Expert Opin Biol Ther 8: 1759-1772.
5. de Jong R, Altare F, Haagen IA, Elferink DG, Boer T, et al. (1998) Severe mycobacterial and Salmonella infections in interleukin-12 receptor-deficient patients. Science 280: 1435-1438.
6. Reichenbach J, Rosenzweig S, Doffinger R, Dupuis S, Holland SM, et al. (2001) Mycobacterial diseases in primary immunodeficiencies. Curr Opin Allergy Clin Immunol 1: 503-511.
7. Winthrop KL (2006) Risk and prevention of tuberculosis and other serious opportunistic infections associated with the inhibition of tumor necrosis factor. Nat Clin Pract Rheumatol 2: 602-610.
8. Cooper AM, Khader SA (2008) The role of cytokines in the initiation, expansion, and control of cellular immunity to tuberculosis. Immunol Rev 226: 191-204.
9. Khader SA, Bell GK, Pearl JE, Fountain JJ, Rangel-Moreno J, et al. (2007) IL-23 and IL-17 in the establishment of protective pulmonary CD4(+) T cell responses after vaccination and during Mycobacterium tuberculosis challenge. Nat Immunol 8: 369-377.
10. Mandalakas AM, Starke JR (2005) Current concepts of childhood tuberculosis. Semin Pediatr Infect Dis 16: 93-104.
11. Trunz BB, Fine P, Dye C (2006) Effect of BCG vaccination on childhood tuberculous meningitis and miliary tuberculosis worldwide: a meta-analysis and assessment of cost-effectiveness. Lancet 367: 1173-1180.
12. Vekemans J, Amedei A, Ota MO, D'Elios MM, Goetghebuer T, et al. (2001) Neonatal bacillus Calmette-Guerin vaccination induces adult-like IFN-gamma production by CD4+ T lymphocytes. Eur J Immunol 31: 1531-1535.
13. Miles DJ, van der Sande M, Crozier S, Ojuola O, Palmero MS, et al. (2008) Effects of antenatal and postnatal environments on CD4 T-cell responses to Mycobacterium bovis BCG in healthy infants in the Gambia. Clin Vaccine Immunol 15: 995-1002.
14. Soares AP, Scriba TJ, Joseph S, Harbacheuski R, Murray RA, et al. (2008) Bacillus Calmette-Guerin vaccination of human newborns induces T cells with complex cytokine and phenotypic profiles. J Immunol 180: 3569-3577.
15. Scriba TJ, Kalsdorf B, Abrahams DA, Isaacs F, Hofmeister J, et al. (2008) Distinct, specific IL-17- and IL-22-producing CD4+ T cell subsets contribute to the human anti-mycobacterial immune response. J Immunol 180: 1962-1970.
16. W.H.O. (2007) Global Advisory Committee on Vaccine Safety, 29-30 November 2006. Wkly Epidemiol Rec 82: 18-24.
17. Siegrist CA (2001) Neonatal and early life vaccinology. Vaccine 19: 3331-3346.
18. Mestas J, Hughes CC (2004) Of mice and not men: differences between mouse and human immunology. J Immunol 172: 2731-2738.
19. Kovarik J, Martinez X, Pihlgren M, Bozzotti P, Tao MH, et al. (2000) Limitations of in vivo IL-12 supplementation strategies to induce Th1 early life responses to model viral and bacterial vaccine antigens. Virology 268: 122-131.
20. Roduit C, Bozzotti P, Mielcarek N, Lambert PH, del Giudice G, et al. (2002) Immunogenicity and protective efficacy of neonatal vaccination against Bordetella pertussis in a murine model: evidence for early control of pertussis. Infect Immun 70: 3521-3528.
21. Adkins B, Leclerc C, Marshall-Clarke S (2004) Neonatal adaptive immunity comes of age. Nat Rev Immunol 4: 553-564.
22. Knuf M, Schmitt HJ, Wolter J, Schuerman L, Jacquet JM, et al. (2008) Neonatal vaccination with an acellular pertussis vaccine accelerates the acquisition of pertussis antibodies in infants. J Pediatr 152: 655-660, 660 e651.
23. Dadaglio G, Sun CM, Lo-Man R, Siegrist CA, Leclerc C (2002) Efficient in vivo priming of specific cytotoxic T cell responses by neonatal dendritic cells. J Immunol 168: 2219-2224.
24. Regner M, Martinez X, Belnoue E, Sun CM, Boisgerault F, et al. (2004) Partial activation of neonatal CD11c+ dendritic cells and induction of adult-like CD8+ cytotoxic T cell responses by synthetic microspheres. J Immunol 173: 2669-2674.
25. Barrios C, Brandt C, Berney M, Lambert PH, Siegrist CA (1996) Partial correction of the TH2/TH1 imbalance in neonatal murine responses to vaccine antigens through selective adjuvant effects. Eur J Immunol 26: 2666-2670.
26. Weeratna RD, Brazolot Millan CL, McCluskie MJ, Davis HL (2001) CpG ODN can re-direct the Th bias of established Th2 immune responses in adult and young mice. FEMS Immunol Med Microbiol 32: 65-71.
27. Kamath AT, Rochat AF, Valenti MP, Agger EM, Lingnau K, et al. (2008) Adult-like anti-mycobacterial T cell and in vivo dendritic cell responses following neonatal immunization with Ag85B-ESAT-6 in the IC31 adjuvant. PLoS ONE 3: e3683.
28. Schellack C, Prinz K, Egyed A, Fritz JH,Wittmann B, et al. (2006) IC31, a novel adjuvant signaling via TLR9, induces potent cellular and humoral immune responses. Vaccine 24: 5461-5472.
29. Riedl K, Riedl R, von Gabain A, Nagy E, Lingnau K (2008) The novel adjuvant IC31 strongly improves influenza vaccine-specific cellular and humoral immune responses in young adult and aged mice. Vaccine 26: 3461-3468.
30. Levy O (2007) Innate immunity of the newborn: basic mechanisms and clinical correlates. Nat Rev Immunol 7: 379-390.
31. Willems F, Vollstedt S, Suter M (2009) Phenotype and function of neonatal DC. Eur J Immunol 39: 26-35.
32. Holten-Andersen L, Doherty TM, Korsholm KS, Andersen P (2004) Combination of the cationic surfactant dimethyl dioctadecyl ammonium bromide and synthetic mycobacterial cord factor as an efficient adjuvant for tuberculosis subunit vaccines. Infect Immun 72: 1608-1617.
33. Davidsen J, Rosenkrands I, Christensen D, Vangala A, Kirby D, et al. (2005) Characterization of cationic liposomes based on dimethyldioctadecylammonium and synthetic cord factor from M. tuberculosis (trehalose 6,6′-dibehenate)-a novel adjuvant inducing both strong CMI and antibody responses. Biochim Biophys Acta 1718: 22-31.
34. Agger EM, Rosenkrands I, Hansen J, Brahimi K, Vandahl BS, et al. (2008) Cationic liposomes formulated with synthetic mycobacterial cordfactor (CAF01): a versatile adjuvant for vaccines with different immunological requirements. PLoS ONE 3: e3116.
35. Werninghaus K, Babiak A, Gross O, Holscher C, Dietrich H, et al. (2009) Adjuvanticity of a synthetic cord factor analogue for subunit Mycobacterium tuberculosis vaccination requires FcRgamma-Syk-Card9-dependent innate immune activation. J Exp Med 206: 89-97.
36. Olsen AW, Williams A, Okkels LM, Hatch G, Andersen P (2004) Protective effect of a tuberculosis subunit vaccine based on a fusion of antigen 85B and ESAT-6 in the aerosol guinea pig model. Infect Immun 72: 6148-6150.
37. Cendron D, Ingoure S, Martino A, Casetti R, Horand F, et al. (2007) A tuberculosis vaccine based on phosphoantigens and fusion proteins induces distinct gammadelta and alphabeta T cell responses in primates. Eur J Immunol 37: 549-565.
38. Langermans JA, Doherty TM, Vervenne RA, van der Laan T, Lyashchenko K, et al. (2005) Protection of macaques against Mycobacterium tuberculosis infection by a subunit vaccine based on a fusion protein of antigen 85B and ESAT-6. Vaccine 23: 2740-2750.
39. Korsholm KS, Agger EM, Foged C, Christensen D, Dietrich J, et al. (2007) The adjuvant mechanism of cationic dimethyldioctadecylammonium liposomes. Immunology.
40. Kamath AT, Valenti MP, Rochat AF, Agger EM, Lingnau K, et al. (2008) Protective anti-mycobacterial T cell responses through exquisite in vivo activation of vaccine-targeted dendritic cells. Eur J Immunol 38: 1247-1256.
41. Henri S, Vremec D, Kamath A, Waithman J, Williams S, et al. (2001) The dendritic cell populations of mouse lymph nodes. J Immunol 167: 741-748.
42. Siegrist CA (2007) The challenges of vaccine responses in early life: selected examples. J Comp Pathol 137 Suppl 1: S4-9.
43. Agger EM, Rosenkrands I, Olsen AW, Hatch G, Williams A, et al. (2006) Protective immunity to tuberculosis with Ag85B-ESAT-6 in a synthetic cationic adjuvant system IC31. Vaccine 24: 5452-5460.
44. Tacken PJ, de Vries IJ, Torensma R, Figdor CG (2007) Dendritic-cell immunotherapy: from ex vivo loading to in vivo targeting. Nat Rev Immunol 7: 790-802.
45. Teoh D, Johnson LA, Hanke T, McMichael AJ, Jackson DG (2009) Blocking development of a CD8+ T cell response by targeting lymphatic recruitment of APC. J Immunol 182: 2425-2431.
46. Randolph GJ, Ochando J, Partida-Sanchez S (2008) Migration of dendritic cell subsets and their precursors. Annu Rev Immunol 26: 293-316.
47. Ruedl C, Koebel P, Bachmann M, Hess M, Karjalainen K (2000) Anatomical origin of dendritic cells determines their life span in peripheral lymph nodes. J Immunol 165: 4910-4916.
48. Kamath AT, Henri S, Battye F, Tough DF, Shortman K (2002) Developmental kinetics and lifespan of dendritic cells in mouse lymphoid organs. Blood 100: 1734-1741.
49. Hou WS, Van Parijs L (2004) A Bcl-2-dependent molecular timer regulates the lifespan and immunogenicity of dendritic cells. Nat Immunol 5: 583-589.
50. Weinrich Olsen A, van Pinxteren LA, Meng Okkels L, Birk Rasmussen P, Andersen P (2001) Protection of mice with a tuberculosis subunit vaccine based on a fusion protein of antigen 85b and esat-6. Infect Immun 69: 2773-2778.
51. Gillis S, Ferm MM, Ou W, Smith KA (1978) T cell growth factor: parameters of production and a quantitative microassay for activity. J Immunol 120: 2027-2032.
52. Martinez X, Regner M, Kovarik J, Zarei S, Hauser C, et al. (2003) CD4-independent protective cytotoxic T cells induced in early life by a non-replicative delivery system based on virus-like particles. Virology 305: 428-435.